Capstone Holding Corp. Delays 10-Q Filing

Capstone Therapeutics ( (CAPS) ) has released a notification of late filing.

Capstone Holding Corp. has announced a delay in filing its Form 10-Q (Quarter Report) for the financial period ending June 30, 2025. The primary reason for this delay is the company’s ongoing efforts to complete its financial statements and disclosures, coupled with the need for additional time by its independent accounting firm to review the financial data. Capstone anticipates filing the report within five calendar days following the original due date. The company does not expect any significant changes in its financial results compared to the same period last year. Capstone is actively working to ensure compliance, with the notification signed by CEO Matthew E. Lipman.

Spark’s Take on CAPS Stock

According to Spark, TipRanks’ AI Analyst, CAPS is a Neutral.

Capstone Therapeutics’ overall stock score reflects significant financial challenges and poor valuation. However, recent strategic acquisitions and positive corporate events provide potential growth opportunities. Technical indicators suggest a neutral to slightly bearish outlook, indicating caution for potential investors.

To see Spark’s full report on CAPS stock, click here.

More about Capstone Therapeutics

Average Trading Volume: 438,722

Technical Sentiment Signal: Sell

Current Market Cap: $7.05M

Find detailed analytics on CAPS stock on TipRanks’ Stock Analysis page.